Peginterferon alfa-2b - Enzon/Merck & Co.

Drug Profile

Peginterferon alfa-2b - Enzon/Merck & Co.

Alternative Names: Cylatron; Interferon-alpha-2b macrogol; Intron A Peg; PEG interferon-alpha-2b; PEG-Intron; PEG-Intron A; PEG-Intron-A; Pegatron; PEGIFN; PegIntron; Pegintron; Pegtron; Pegylated IFN alfa-2b; Pegylated IFN-alpha 2b; Pegylated interferon-alpha-2b; pIFN - alpha 2b; Polyethylene glycol interferon-alpha-2b; SCH 54031; Sylatron; ViraferonPeg

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Enzon Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Hoosier Cancer Research Network; Merck & Co; Novartis; Schering-Plough; University of Pittsburgh; VU University Medical Center; Wistar Institute
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C; Malignant melanoma
  • Phase II Cholangiocarcinoma; HIV infections
  • Discontinued Chronic myeloid leukaemia; Multiple sclerosis; Polycythaemia vera; Solid tumours

Most Recent Events

  • 14 Aug 2018 Phase I development is ongoing in Malignant melanoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (SC) (NCT02112032)
  • 24 Jun 2018 Biomarkers information updated
  • 13 Jun 2018 Merk prematurely terminates a phase II/III trial in Melanoma (Adjuvant therapy, Late-stage disease, Metastatic disease) due to sub-optimal accrual (SC, IV) (NCT03552549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top